Table 4.
Comparison of treatments and outcomes based on primary site
| Characteristics | Total cases (n = 581) |
Small intestine (n = 162) |
Ileocecal region (n = 231) |
Large intestine (n = 125) |
Multiple intestinal involvement (n = 63) |
|---|---|---|---|---|---|
| Treatment* | |||||
| Chemotherapy | 521 (89.7%) | 143 (88.3%) | 213 (92.2%) | 105 (84.0%) | 60 (95.2%) |
| Surgical resection | 289 (49.7%) | 74 (45.7%) | 148 (64.1%) | 49 (39.2%) | 18 (28.6%) |
| Radiotherapy | 56 (9.6%) | 21 (13.0%) | 18 (7.8%) | 13 (10.4%) | 4 (6.3%) |
| Response | |||||
| Complete response | 360 (62.0%) | 94 (58.0%) | 164 (71.0%) | 71 (57.0%) | 31 (49.0%) |
| Partial response | 62 (10.7%) | 16 (9.9%) | 16 (6.9%) | 19 (15.0%) | 11 (18.0%) |
| Outcome | |||||
| Relapse or Progression | 199 (34.3%) | 57 (35.2%) | 65 (28.1%) | 50 (40.0%) | 27 (42.9%) |
| Dead | 152 (26.2%) | 44 (27.2%) | 47 (20.3%) | 36 (28.8%) | 25 (39.7%) |
| Survival | |||||
| Median OS | Not reached | Not reached | Not reached | 140 months | 61 months |
| 5-year OS | 67% | 65% | 72% | 67% | 55% |
| Median PFS | 88 months | 55 months | 115 months | 66 months | 28 months |
| 5-year PFS | 53% | 50% | 62% | 50% | 37% |
*Some patients were treated with combined modality such as surgery plus chemotherapy. Thus, the sum of number of each treatment is larger than total number of patients.